Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-001986-41 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative therapy (LIR).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Oral treatment |
|
| 2 | Experimental | Oral treatment |
|
| 3 | Placebo Comparator | Oral treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NKTR-118 | Drug | 12.5 mg oral tablet once daily |
| |
| NKTR-118 |
| Measure | Description | Time Frame |
|---|---|---|
| Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 | Responder was defined as having at least 3 spontaneous bowel movements (SBMs)/week with at least 1 SBM/week increase over baseline for at least 9 out of the 12 treatment weeks and 3 out of the last 4 treatment weeks during the double-blind treatment period. An SBM is a bowel movement occurring 24 hours or more since the last use of rescue medication. | Baseline (Week 1) to end of treatment (Week 12) |
| Measure | Description | Time Frame |
|---|---|---|
| Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12 | Responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline for at least 9 out of 12 weeks and at least 3 out of the last 4 weeks. | Baseline (Week 1) to end of treatment (Week 12) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Sostek | AstraZeneca | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Mobile | Alabama | United States | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27342744 | Derived | Lawson R, King F, Marsh K, Altincatal A, Cimen A. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. Adv Ther. 2016 Aug;33(8):1331-46. doi: 10.1007/s12325-016-0365-y. Epub 2016 Jun 24. | |
| 26535126 | Derived | Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015 Oct;3(5):471-80. doi: 10.1177/2050640615604543. |
| Label | URL |
|---|---|
| Clinical Study Protocol | View source |
Not provided
The study duration was up to 18 weeks, consisting of an initial screening period lasting up to 2 weeks, a 2-week OIC confirmation period, during which the diagnosis of OIC and stability of the opioid regimen were confirmed, a 12-week treatment period, and a follow-up visit 2 weeks after the last dose of study drug.
This multicenter study was conducted in Belgium, Croatia, Czech Republic, Hungary, Spain, Sweden, United Kingdom, and the United States between 28 March 2011 and 20 September 2012.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | NKTR-118 12.5 mg | NKTR-118 12.5 QD, oral treatment |
| FG001 | NKTR-118 25 mg | NKTR-118 25 mg QD, oral treatment |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
25 mg oral tablet once daily |
|
| Placebo | Drug | Placebo to NKTR-118 |
|
| Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours |
| 12 weeks |
| Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12 | 12 weeks |
| Change From Baseline in Degree of Straining | A single-item straining question was asked via the eDiary: "How much did you strain during your bowel movement?" Patients responded on a 5 point Likert scale: 1=Not at all; 2=A little bit; 3=A moderate amount; 4=A great deal; 5=An extreme amount. A negative change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Stool Consistency (Bristol Stool Scale) | Patients rated stool consistency through completion of the BSS after each BM. The 7 stool types are: 1. Separate hard lumps, like nuts (hard to pass); 2. Sausage-shaped, but lumpy; 3. Like sausage, but with cracks on its surface; 4. Like a sausage or snake, smooth and soft; 5. Soft blobs with clear cut edges (passed easily); 6. Fluffy pieces with ragged edges, a mushy stool; 7. Watery, no solid pieces. A positive change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement) | A single-item question on the completeness of evacuation, developed and validated through 1:1 interviews with OIC patients, was asked via the eDiary: "Did you feel like your bowels were completely empty after the bowel movement?" Patients provided a yes or a no response. A positive change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Mean Spontaneous Bowel Movements/Week | The number of spontaneous bowel movements/week was determined from the patient's eDiary. | Baseline (Week 1) to end of treatment (Week 12) |
| Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup | Time to first post-dose laxation without the use of rescue laxatives within the last 24 hours was calculated in hours as: Date/Time of first post-dose laxation without rescue - First dose date/time. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) | The PAC-SYM questionnaire is a 12-item questionnaire that evaluates the severity of symptoms of constipation in 3 domains (stool, rectal, and abdominal symptoms) on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe) in the 2 weeks (14 days) prior to assessment. Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items (ie, symptoms). The range of the domain or total score is 0 (response is 'absent' for each item) to 4 (response is 'very severe' for each item). A negative change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain | The PAC-QOL scale is a 28-item self-report instrument designed to evaluate the burden of constipation on patients' everyday functioning and well-being in the 2 weeks (14 days) prior to assessment. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The instrument can be used to generate an overall score, but is also reported to assess 4 specific constipation-related domains including: 1) Worries and concerns (11 items), 2) Physical discomfort (4 items), 3) Psychosocial discomfort (8 items), and 4) Satisfaction (5 items). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items. The range of the domain or total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item). A negative change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Pell City |
| Alabama |
| United States |
| Research Site | Mesa | Arizona | United States |
| Research Site | Phoenix | Arizona | United States |
| Research Site | Sun Lakes | Arizona | United States |
| Research Site | Tucson | Arizona | United States |
| Research Site | Jonesboro | Arkansas | United States |
| Research Site | Little Rock | Arkansas | United States |
| Research Site | North Little Rock | Arkansas | United States |
| Research Site | Sherwood | Arkansas | United States |
| Research Site | Chino | California | United States |
| Research Site | La Jolla | California | United States |
| Research Site | Lincoln | California | United States |
| Research Site | Modesto | California | United States |
| Research Site | Colorado Springs | Colorado | United States |
| Research Site | Stamford | Connecticut | United States |
| Research Site | Bradenton | Florida | United States |
| Research Site | Delray Beach | Florida | United States |
| Research Site | Gainesville | Florida | United States |
| Research Site | Miami | Florida | United States |
| Research Site | Miami Springs | Florida | United States |
| Research Site | Ocala | Florida | United States |
| Research Site | Sanford | Florida | United States |
| Research Site | St. Petersburg | Florida | United States |
| Research Site | Tampa | Florida | United States |
| Research Site | West Palm Beach | Florida | United States |
| Research Site | Conyers | Georgia | United States |
| Research Site | John's Creek | Georgia | United States |
| Research Site | Peoria | Illinois | United States |
| Research Site | Council Bluffs | Iowa | United States |
| Research Site | Wichita | Kansas | United States |
| Research Site | Baton Rouge | Louisiana | United States |
| Research Site | Shreveport | Louisiana | United States |
| Research Site | Baltimore | Maryland | United States |
| Research Site | Chestnut Hill | Massachusetts | United States |
| Research Site | Watertown | Massachusetts | United States |
| Research Site | Livonia | Michigan | United States |
| Research Site | Saint Clair Shores | Michigan | United States |
| Research Site | Florissant | Missouri | United States |
| Research Site | Henderson | Nevada | United States |
| Research Site | Freehold | New Jersey | United States |
| Research Site | Voorhees Township | New Jersey | United States |
| Research Site | Willingboro | New Jersey | United States |
| Research Site | Great Neck | New York | United States |
| Research Site | Hartsdale | New York | United States |
| Research Site | North Massapequa | New York | United States |
| Research Site | Chapel Hill | North Carolina | United States |
| Research Site | Morrisville | North Carolina | United States |
| Research Site | Winston-Salem | North Carolina | United States |
| Research Site | Bellevue | Ohio | United States |
| Research Site | Downingtown | Pennsylvania | United States |
| Research Site | Jenkintown | Pennsylvania | United States |
| Research Site | Philadelphia | Pennsylvania | United States |
| Research Site | Pottstown | Pennsylvania | United States |
| Research Site | Anderson | South Carolina | United States |
| Research Site | Myrtle Beach | South Carolina | United States |
| Research Site | Chattanooga | Tennessee | United States |
| Research Site | Jackson | Tennessee | United States |
| Research Site | Milan | Tennessee | United States |
| Research Site | Austin | Texas | United States |
| Research Site | Houston | Texas | United States |
| Research Site | Hurst | Texas | United States |
| Research Site | Marshall | Texas | United States |
| Research Site | San Antonio | Texas | United States |
| Research Site | Sugarland | Texas | United States |
| Research Site | Clinton | Utah | United States |
| Research Site | St. George | Utah | United States |
| Research Site | West Jordan | Utah | United States |
| Research Site | Edegem | Belgium | Belgium |
| Research Site | Roeselare | Belgium | Belgium |
| Research Site | Antwerp | Belgium |
| Research Site | Leuven | Belgium |
| Research Site | Moerkerke | Belgium |
| Research Site | Mouscron | Belgium |
| Research Site | Bjelovar | Croatia |
| Research Site | Osijek | Croatia |
| Research Site | Susak | Croatia |
| Research Site | Zagreb | Croatia |
| Research Site | Choceň | Czechia |
| Research Site | Pardubice | Czechia |
| Research Site | Prague | Czechia |
| Research Site | Zlín | Czechia |
| Research Site | Baja | Hungary |
| Research Site | Budapest | Hungary |
| Research Site | Kecskemét | Hungary |
| Research Site | Miskolc | Hungary |
| Research Site | Pusztaszer | Hungary |
| Research Site | Sátoraljaújhely | Hungary |
| Research Site | Szeged | Hungary |
| Research Site | Szikszó | Hungary |
| Research Site | Úrhida | Hungary |
| Research Site | Zalaegerszeg | Hungary |
| Research Site | Málaga | Andalusia | Spain |
| Research Site | Barcelona | Catalonia | Spain |
| Research Site | Centelles (barcelona) | Catalonia | Spain |
| Research Site | L'Hospitalet de Llobregat | Catalu?a | Spain |
| Research Site | Vic | Catalu?a | Spain |
| Research Site | Fuenlabrada | Madrid | Spain |
| Research Site | Almería | Spain |
| Research Site | Lleida | Spain |
| Research Site | Madrid | Spain |
| Research Site | Santiago de Compostela | Spain |
| Research Site | Valencia | Spain |
| Research Site | Valladolid | Spain |
| Research Site | Gothenburg | Sweden |
| Research Site | Lund | Sweden |
| Research Site | Stockholm | Sweden |
| Research Site | Vällingby | Sweden |
| Research Site | Ayrshire | AYR | United Kingdom |
| Research Site | Chesterfield | Derby | United Kingdom |
| Research Site | Derby | Derby | United Kingdom |
| Research Site | Plymouth | Devon | United Kingdom |
| Research Site | London | Gt Lon | United Kingdom |
| Research Site | Royton | Lancashire | United Kingdom |
| Research Site | Thornton-Cleveleys | Lancashire | United Kingdom |
| Research Site | Norwich | Norflk | United Kingdom |
| Research Site | Barry | S Glam | United Kingdom |
| Research Site | Bath | Somer | United Kingdom |
| Research Site | Glasgow | Strath | United Kingdom |
| Research Site | Coventry | Warwks | United Kingdom |
| 24896818 | Derived | Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4. |
| Clinical\_Study\_Report\_Synopsis\_D3820C00005 | View source |
| FG002 |
| Placebo |
Placebo QD, oral treatment |
| COMPLETED |
|
| NOT COMPLETED |
|
|
A total of 4 patients (2 patients in the NKTR-118 25 mg and 1 patient each in the NKTR-118 12.5 mg and placebo groups) had been previously randomized within the NKTR-118 program at a different study center. These patients were excluded from the ITT and Safety analysis sets. Baseline characteristics are summarized based on the ITT analysis set.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | NKTR-118 12.5 mg | NKTR-118 12.5 QD, oral treatment |
| BG001 | NKTR-118 25 mg | NKTR-118 25 mg QD, oral treatment |
| BG002 | Placebo | Placebo QD, oral treatment |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | Participants |
| ||||||||||||||||
| Baseline laxative response status | Laxative response status was determined at the screening visit (Visit 1) based on the Baseline Laxative Response Status Questionnaire. Patients were classified as: Laxative Inadequate Responder (LIR: patients who reported moderate, severe, or very severe symptoms in at least 1 of the 4 stool symptom domains); Laxative Adequate Responder (LAR: patients who reported no symptoms or only mild symptoms); and Laxative Unknown Responder (LUR: patients who had not taken laxatives over the previous 2 weeks or who had taken 1 or more laxative classes on <4 days over the previous 2 weeks). | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 | Responder was defined as having at least 3 spontaneous bowel movements (SBMs)/week with at least 1 SBM/week increase over baseline for at least 9 out of the 12 treatment weeks and 3 out of the last 4 treatment weeks during the double-blind treatment period. An SBM is a bowel movement occurring 24 hours or more since the last use of rescue medication. | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Number | Number of patients | Baseline (Week 1) to end of treatment (Week 12) |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12 | Responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline for at least 9 out of 12 weeks and at least 3 out of the last 4 weeks. | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. The LIR subgroup used 1 or more laxative classes for at least 4 days in the 2 weeks prior to entry and reported moderate to very severe symptoms. | Posted | Number | Number of patients | Baseline (Week 1) to end of treatment (Week 12) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Median | 95% Confidence Interval | Hours | 12 weeks |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12 | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | Number of Days | 12 weeks |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Degree of Straining | A single-item straining question was asked via the eDiary: "How much did you strain during your bowel movement?" Patients responded on a 5 point Likert scale: 1=Not at all; 2=A little bit; 3=A moderate amount; 4=A great deal; 5=An extreme amount. A negative change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Stool Consistency (Bristol Stool Scale) | Patients rated stool consistency through completion of the BSS after each BM. The 7 stool types are: 1. Separate hard lumps, like nuts (hard to pass); 2. Sausage-shaped, but lumpy; 3. Like sausage, but with cracks on its surface; 4. Like a sausage or snake, smooth and soft; 5. Soft blobs with clear cut edges (passed easily); 6. Fluffy pieces with ragged edges, a mushy stool; 7. Watery, no solid pieces. A positive change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement) | A single-item question on the completeness of evacuation, developed and validated through 1:1 interviews with OIC patients, was asked via the eDiary: "Did you feel like your bowels were completely empty after the bowel movement?" Patients provided a yes or a no response. A positive change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | Percent days/week | Baseline (Week 1) to end of treatment (Week 12) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Mean Spontaneous Bowel Movements/Week | The number of spontaneous bowel movements/week was determined from the patient's eDiary. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | Number of SBMs/week | Baseline (Week 1) to end of treatment (Week 12) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup | Time to first post-dose laxation without the use of rescue laxatives within the last 24 hours was calculated in hours as: Date/Time of first post-dose laxation without rescue - First dose date/time. | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Median | 95% Confidence Interval | hours | Baseline (Week 1) to end of treatment (Week 12) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) | The PAC-SYM questionnaire is a 12-item questionnaire that evaluates the severity of symptoms of constipation in 3 domains (stool, rectal, and abdominal symptoms) on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe) in the 2 weeks (14 days) prior to assessment. Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items (ie, symptoms). The range of the domain or total score is 0 (response is 'absent' for each item) to 4 (response is 'very severe' for each item). A negative change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who randomized multiple times at different centers. MMRM analysis includes all patients with baseline and at least 1 post-baseline assessment, while the Ns at Week 12 reflect patients providing data at Week 12. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain | The PAC-QOL scale is a 28-item self-report instrument designed to evaluate the burden of constipation on patients' everyday functioning and well-being in the 2 weeks (14 days) prior to assessment. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The instrument can be used to generate an overall score, but is also reported to assess 4 specific constipation-related domains including: 1) Worries and concerns (11 items), 2) Physical discomfort (4 items), 3) Psychosocial discomfort (8 items), and 4) Satisfaction (5 items). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items. The range of the domain or total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item). A negative change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who randomized multiple times at different centers. MMRM analysis includes all patients with baseline and at least 1 post-baseline assessment, while the Ns at Week 12 reflect patients providing data at Week 12. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
|
Not provided
Adverse Events are reported for those subjects who were randomized and receieved at least one dose of study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | NKTR-118 12.5 mg | 14 | 230 | 90 | 230 | |||
| EG001 | NKTR-118 25 mg | 8 | 232 | 112 | 232 | |||
| EG002 | Placebo | 12 | 231 | 73 | 231 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ACUTE MYOCARDIAL INFARCTION | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ANGINA PECTORIS | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| VERTIGO | Ear and labyrinth disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PANCREATITIS | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| RECTAL HAEMORRHAGE | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| POSTOPERATIVE WOUND INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| SEPSIS | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| URINARY TRACT INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| WOUND INFECTION STAPHYLOCOCCAL | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| ACCIDENTAL OVERDOSE | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| BRAIN CONTUSION | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| POST LAMINECTOMY SYNDROME | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| SUBDURAL HAEMORRHAGE | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| CHEST X-RAY ABNORMAL | Investigations | MedDRA 15.0 | Systematic Assessment |
| |
| CSF CULTURE POSITIVE | Investigations | MedDRA 15.0 | Systematic Assessment |
| |
| DEHYDRATION | Metabolism and nutrition disorders | MedDRA 15.0 | Systematic Assessment |
| |
| INTERVERTEBRAL DISC DEGENERATION | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| OSTEOARTHRITIS | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| OSTEONECROSIS | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| APHASIA | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| GRAND MAL CONVULSION | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| MIGRAINE | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PARAESTHESIA | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| SYNCOPE | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ALCOHOL ABUSE | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ANXIETY | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DEPRESSION | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
| |
| MAJOR DEPRESSION | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
| |
| MENTAL STATUS CHANGES | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
| |
| NEPHROLITHIASIS | Renal and urinary disorders | MedDRA 15.0 | Systematic Assessment |
| |
| RENAL FAILURE ACUTE | Renal and urinary disorders | MedDRA 15.0 | Systematic Assessment |
| |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Respiratory, thoracic and mediastinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PULMONARY EMBOLISM | Respiratory, thoracic and mediastinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| RESPIRATORY FAILURE | Respiratory, thoracic and mediastinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ACCELERATED HYPERTENSION | Vascular disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HYPERTENSION | Vascular disorders | MedDRA 15.0 | Systematic Assessment |
| |
| MALIGNANT HYPERTENSION | Vascular disorders | MedDRA 15.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ABDOMINAL DISTENSION | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN UPPER | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| FLATULENCE | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| NAUSEA | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| VOMITING | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| FATIGUE | General disorders | MedDRA 15.0 | Systematic Assessment |
| |
| NASOPHARYNGITIS | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| SINUSITIS | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| FALL | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| BLOOD THYROID STIMULATING HORMONE INCREASED | Investigations | MedDRA 15.0 | Systematic Assessment |
| |
| ARTHRALGIA | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| BACK PAIN | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DIZZINESS | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ANXIETY | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HYPERTENSION | Vascular disorders | MedDRA 15.0 | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Mark Sostek | AstraZeneca | ClinicalTrialTransparency@astrazeneca.com |
| ID | Term |
|---|---|
| D000079689 | Opioid-Induced Constipation |
| ID | Term |
|---|---|
| D003248 | Constipation |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000589308 | naloxegol |
Not provided
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| Other |
|
| Laxative Adequate Response (LAR) |
|
| Laxative Unknown Response (LUR) |
|
| Cochran-Mantel-Haenszel |
| 0.021 |
| Risk Ratio (RR) |
| 1.348 |
| 2-Sided |
| 95 |
| 1.045 |
| 1.739 |
| No |
| Superiority or Other |
| Participants |
|
|
|
|
|
|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|
|
|
|
Placebo QD, oral treatment |
|
|
|
NKTR-118 25 mg QD, oral treatment |
| OG002 | Placebo | Placebo QD, oral treatment |
|
|
|